An engineered triphasic biomaterial scaffold successfully recreated the cranial suture stem cell niche lost in ...

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that ...

Bone regeneration is a complex process, and existing methods to aid regeneration including transplants and growth factor transmissions face limitations such as the high cost. But recently, a ...

Craniosynostosis, the premature fusion of the top of the skull in infants, is caused by an abnormal excess of a previously unknown type of bone-forming stem cell, according to a preclinical study.

A research team from the Department of Orthopedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine at the University of Hong Kong (HKUMed), has developed a titanium implant ...

Bone Biologics financing announcement highlights Nasdaq Composite activity, orthobiologics development, healthcare sector ...

Please provide your email address to receive an email when new articles are posted on . Biocomposites announced Renovos Biologics received FDA breakthrough device designation of its Renovite bone ...

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc., an orthobiologics technology company located in Colleyville, Texas, announced today 510(k) clearance of Mg OSTEOCRETE from the U.S. Food and ...

Over 400,000 spinal fusion surgeries are performed annually in the United States and as the population ages, that number is expected to rise. The goal of many spinal fusion surgeries is to reduce or ...

It held an 8% share of the Asia-Pacific market in 2025. South Korea's bone grafts and substitutes market is forecast to expand at a compound annual growth rate of 4% through 2033, driven by higher ...